Biopharmaceutical Company Publishes Positive Data For Crohn's Disease Treatment
Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease.
In a landmark study published in the peer-reviewed journal Antibiotics, RedHill Biopharma Ltd. (Nasdaq: RDHL) revealed significant findings from its Phase 3 clinical trial involving RHB-104, an oral antimicrobial therapy for Crohn's disease. The study has set a new precedent by demonstrating a 64% increase in efficacy compared to the standard of care (SoC). $Redhill Biopharma (RDHL.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
72991267 : I’m setting Limit sales orders at 3.00 per share so they can’t short sell my shares!! Anti Radiation poison drug Should be in High Demand by governments around the world.
EZ_money 72991267 : why are you afraid of WW3 becoming nuclear?